Compare ANY & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANY | BIVI |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 9.2M |
| IPO Year | N/A | N/A |
| Metric | ANY | BIVI |
|---|---|---|
| Price | $0.27 | $1.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 441.0K | 135.4K |
| Earning Date | 11-04-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,099,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.29 | $1.10 |
| 52 Week High | $1.26 | $22.90 |
| Indicator | ANY | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 31.16 | 41.02 |
| Support Level | $0.32 | $1.14 |
| Resistance Level | $0.38 | $1.26 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 7.16 | 30.51 |
Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Bitcoin Mining and Service and Product. The Bitcoin Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.